Search Within

GDMT, Medicine

  1. "Early Drug Development Service"
Formats
  1. Journal Article (42)
  2. Meeting Abstract (29)
  3. Book Section (1)
Groups
  1. Department of Medicine (72)
  2. Early Drug Development Service (72)
  3. Gynecologic Medicine Service (72)
  4. Gynecology Disease Management Team (72)
  5. Solid Tumor Oncology Division (72)
  6. Epidemiology and Biostatistics (35)

More Groups

People
  1. David Hyman (61)
  2. Carol Aghajanian (36)
  3. Rachel Grisham (33)
  4. Vicky Makker (25)
  5. Martee Hensley (24)
  6. Alexia Iasonos (23)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (1)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (21)
  2. Gynecologic Oncology (10)
  3. Clinical Cancer Research (8)
  4. JCO Precision Oncology (5)
  5. Annals of Oncology (3)
  6. Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (26)
  2. Elsevier Inc. (13)
  3. American Association for Cancer Research (12)
  4. Lippincott Williams & Wilkins (5)
  5. Oxford University Press (3)
  6. Springer (3)

More Publishers

Results (72)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Retrospective analysis of BRCA-altered uterine sarcoma treated with poly(ADP-ribose) polymerase inhibitors
    Journal Article

    Rao, M.; Merrill, M.; Troxel, M.; Chiang, S.; Momeni-Boroujeni, A.; Hensley, M. L.; Schram, A. M.
    JCO Precision Oncology (2025)

    Fulltext@MSK | Save
  • Genotypically-selected pan cancer trial of camonsertib with palliative radiation in the treatment of metastatic tumors harboring an ataxia-telangiectasia mutated (ATM) mutation
    Meeting Abstract

    Lee, N. Y.; Michelle, R.; Huang, M.; Guo, R.; Ferreira, V.; Merril, M.; Sgroe, E.; Unger, T.; Koehler, M.; Setton, J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)
    Meeting Abstract

    Schram, A.; Eskander, R.; Sill, M.; Hagemann, A.; Waggoner, S.; Press, J.; Ghamande, S.; Zivanovic, O.; Bottsford-Miller, J.; Aghajanian, C.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
    Journal Article

    Movva, S.; Seier, K.; Avutu, V.; Banks, L. B.; Chan, J.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, Ciara M.; Keohan, M. L.; Meyers, P. A.; Cohen, S. M.; Hensley, M. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Spectrum of BRAF mutations and gene rearrangements in ovarian serous carcinoma
    Journal Article

    Chui, M. H.; Chang, J. C.; Zhang, Y.; Zehir, A.; Schram, A. M.; Konner, J.; Drilon, A. E.; da Cruz Paula, A.; Weigelt, B.; Grisham, R. N.
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save